Novel molecular targets for the therapy of urothelial cancer

Bagi Jana, Yan Zhou

    Research output: Contribution to journalArticle

    6 Citations (Scopus)

    Abstract

    First-line platinum-based chemotherapy combinations are considered standard-of-care in locally advanced and metastatic urothelial cancer. However, longterm outcomes, including disease-specific and overall survival, remain poor. In addition, a number of patients with advanced urothelial carcinoma have co-existing medical issues that preclude the use of conventional chemotherapy. Improvements in our understanding over the molecular mechanisms of urothelial cancer have led to first-generation clinical trials evaluating novel agents targeting molecular pathways that may be relevant, at least in sub-populations. Emerging information regarding outcome with agents targeting novel molecular targets in advanced urothelial cancer is discussed in this review.

    Original languageEnglish (US)
    Pages (from-to)4557-4568
    Number of pages12
    JournalAnticancer Research
    Volume35
    Issue number9
    StatePublished - Sep 1 2015

    Fingerprint

    Neoplasms
    Standard of Care
    Combination Drug Therapy
    Platinum
    Therapeutics
    Clinical Trials
    Carcinoma
    Drug Therapy
    Survival
    Population

    Keywords

    • Novel molecular targets
    • Review
    • Targeted therapy
    • Transitional cell carcinoma
    • Urothelial cancer

    ASJC Scopus subject areas

    • Cancer Research
    • Oncology

    Cite this

    Novel molecular targets for the therapy of urothelial cancer. / Jana, Bagi; Zhou, Yan.

    In: Anticancer Research, Vol. 35, No. 9, 01.09.2015, p. 4557-4568.

    Research output: Contribution to journalArticle

    Jana, B & Zhou, Y 2015, 'Novel molecular targets for the therapy of urothelial cancer', Anticancer Research, vol. 35, no. 9, pp. 4557-4568.
    Jana, Bagi ; Zhou, Yan. / Novel molecular targets for the therapy of urothelial cancer. In: Anticancer Research. 2015 ; Vol. 35, No. 9. pp. 4557-4568.
    @article{0e5860390e2d4e2c973eb34863253129,
    title = "Novel molecular targets for the therapy of urothelial cancer",
    abstract = "First-line platinum-based chemotherapy combinations are considered standard-of-care in locally advanced and metastatic urothelial cancer. However, longterm outcomes, including disease-specific and overall survival, remain poor. In addition, a number of patients with advanced urothelial carcinoma have co-existing medical issues that preclude the use of conventional chemotherapy. Improvements in our understanding over the molecular mechanisms of urothelial cancer have led to first-generation clinical trials evaluating novel agents targeting molecular pathways that may be relevant, at least in sub-populations. Emerging information regarding outcome with agents targeting novel molecular targets in advanced urothelial cancer is discussed in this review.",
    keywords = "Novel molecular targets, Review, Targeted therapy, Transitional cell carcinoma, Urothelial cancer",
    author = "Bagi Jana and Yan Zhou",
    year = "2015",
    month = "9",
    day = "1",
    language = "English (US)",
    volume = "35",
    pages = "4557--4568",
    journal = "Anticancer Research",
    issn = "0250-7005",
    publisher = "International Institute of Anticancer Research",
    number = "9",

    }

    TY - JOUR

    T1 - Novel molecular targets for the therapy of urothelial cancer

    AU - Jana, Bagi

    AU - Zhou, Yan

    PY - 2015/9/1

    Y1 - 2015/9/1

    N2 - First-line platinum-based chemotherapy combinations are considered standard-of-care in locally advanced and metastatic urothelial cancer. However, longterm outcomes, including disease-specific and overall survival, remain poor. In addition, a number of patients with advanced urothelial carcinoma have co-existing medical issues that preclude the use of conventional chemotherapy. Improvements in our understanding over the molecular mechanisms of urothelial cancer have led to first-generation clinical trials evaluating novel agents targeting molecular pathways that may be relevant, at least in sub-populations. Emerging information regarding outcome with agents targeting novel molecular targets in advanced urothelial cancer is discussed in this review.

    AB - First-line platinum-based chemotherapy combinations are considered standard-of-care in locally advanced and metastatic urothelial cancer. However, longterm outcomes, including disease-specific and overall survival, remain poor. In addition, a number of patients with advanced urothelial carcinoma have co-existing medical issues that preclude the use of conventional chemotherapy. Improvements in our understanding over the molecular mechanisms of urothelial cancer have led to first-generation clinical trials evaluating novel agents targeting molecular pathways that may be relevant, at least in sub-populations. Emerging information regarding outcome with agents targeting novel molecular targets in advanced urothelial cancer is discussed in this review.

    KW - Novel molecular targets

    KW - Review

    KW - Targeted therapy

    KW - Transitional cell carcinoma

    KW - Urothelial cancer

    UR - http://www.scopus.com/inward/record.url?scp=84939606085&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84939606085&partnerID=8YFLogxK

    M3 - Article

    C2 - 26254343

    AN - SCOPUS:84939606085

    VL - 35

    SP - 4557

    EP - 4568

    JO - Anticancer Research

    JF - Anticancer Research

    SN - 0250-7005

    IS - 9

    ER -